• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Revance Therapeutics

edit

Revance Therapeutics, Inc., a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia Biosystems, Inc. Revance Therapeutics, Inc. was founded in 2002 and is based in Mountain View, California.

Recent Milestones

edit

• 
  Revance Therapeutics received $33M in Series E funding. (4/2/13)
  Posted 4/5/13 at 4:45am via biocentury.com
• 
  Revance Therapeutics received $45M in Venture Round funding. (6/10/11)
  Posted 6/10/11 at 6:17pm via finsmes.com
• 
  Revance Therapeutics received $25M in Series D funding. (1/4/10)
  Posted 12/23/09 at 2:49pm via finsmes.com
• 
  Revance Therapeutics added Phyllis Gardner as Director.
  Posted 12/23/09 at 2:49pm
• 
  Revance Therapeutics added Robert Byrnes as Director.
  Posted 12/23/09 at 2:49pm
• 
  Revance Therapeutics added Jim Glasheen as Director.
  Posted 12/23/09 at 2:49pm
• 
  Revance Therapeutics added Frank Kung as Director.
  Posted 12/23/09 at 2:49pm
• 
  Revance Therapeutics added Vicente Trelles as Director.
  Posted 12/23/09 at 2:49pm

Videos

Screenshots

edit

Above: Home Page
Uploaded: 12/26/09

Sources

1. Revance Raises $25M in Series D Financing (finsmes.com) [edit]
2. Revance Therapeutics Closes $45M Financing (finsmes.com) [edit]
3. Revance closes $33 million series E (biocentury.com) [edit]